<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01750112</url>
  </required_header>
  <id_info>
    <org_study_id>31GC1201</org_study_id>
    <nct_id>NCT01750112</nct_id>
  </id_info>
  <brief_title>Treatment of Pectus Excavatum Deformity Using Macrolane Filler</brief_title>
  <official_title>An Open Non Comparative Multicenter Prospective Study to Evaluate Efficacy and Safety of Macrolane VRF20 in Treatment of Pectus Excavatum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharma Consulting Group AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open, non-comparative and baseline-controlled study to evaluate&#xD;
      efficacy and safety of Macrolane VRF20 treatment in 40 subjects with pectus excavatum&#xD;
      deformity.&#xD;
&#xD;
      Each subject participating in the study will be treated with approximately 50-150 ml of&#xD;
      Macrolane VRF20. The amount of study product used will be individually determined in order to&#xD;
      achieve an optimal correction of the deformity in each subject.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PEEQ</measure>
    <time_frame>Jul 2016</time_frame>
    <description>To evaluate improvement from baseline in general self-esteem and emotion at 1, 3, 6, 12 and 24 months after treatment with Macrolane VRF20, using a modified version of the pectus excavatum evaluation questionnaire (PEEQ) before and after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject satisfaction</measure>
    <time_frame>Jul 2016</time_frame>
    <description>Evaluate subject satisfaction at 1, 3, 6, 12 and 24 months after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration</measure>
    <time_frame>Jul 2016</time_frame>
    <description>Estimate duration of Macrolane VRF20 calculated using MRI images at 12 months (and 24 months for a subset of patients).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Placement</measure>
    <time_frame>Jul 2016</time_frame>
    <description>Assess placement using MRI at 1 and 12 months post treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event</measure>
    <time_frame>Jul 2016</time_frame>
    <description>To study safety throughout the study period, i.e. up to 24 months after treatment, based on evaluation of reported Adverse Events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Downtime</measure>
    <time_frame>Jul 2016</time_frame>
    <description>Evaluate recovery time after treatment using 14-days subject diary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Downtime 2</measure>
    <time_frame>Jul 2016</time_frame>
    <description>Evaluate days hospitalized or on sick leave after treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Pectus Excavatum Deformity</condition>
  <arm_group>
    <arm_group_label>Macrolane VRF20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive treatment with Macrolane VRF20 to correct pectus excvatum deformity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Macrolane VRF20</intervention_name>
    <description>Injection treatment with Macrolane VRF20</description>
    <arm_group_label>Macrolane VRF20</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Give verbal and written informed consent to participate in the study.&#xD;
&#xD;
          2. Be a healthy male of 18 years or more.&#xD;
&#xD;
          3. Have a pectus excavatum deformity without functional problems; score 4 in items 10, 11&#xD;
             and 12 of the PEEQ, indicating there is no functional impairment due to the pectus&#xD;
             excavatum deformation.&#xD;
&#xD;
          4. Present normal cardiac function as assessed by ECG and echocardiogram.&#xD;
&#xD;
          5. Present normal pulmonary function as assessed by pulmonary function test.&#xD;
&#xD;
          6. Present a chest X-ray taken within 12 months prior to the baseline visit, without&#xD;
             clinically significant defects to heart, lungs, skeleton, ribs, sternum or spinal cord&#xD;
             except for the pectus excavatum defect, in the opinion of the Investigator.&#xD;
&#xD;
          7. Have the ability to understand and comply with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Score 1, 2 or 3 in either of items 10, 11 and 12 of the PEEQ, indicative of functional&#xD;
             problems due to the pectus excavatum deformity.&#xD;
&#xD;
          2. Previous treatment for the same indication.&#xD;
&#xD;
          3. Known or suspected hypersensitivity to hyaluronic acid based products.&#xD;
&#xD;
          4. BMI &lt; 20.&#xD;
&#xD;
          5. A history of severe allergies manifested by a history of anaphylaxis, or a history or&#xD;
             presence of multiple severe allergies (as judged by the Investigator).&#xD;
&#xD;
          6. Known allergy to any anesthesia planned during the study.&#xD;
&#xD;
          7. Presence of autoimmune disease or other chronic disease that in the opinion of the&#xD;
             Investigator may interfere with the outcome of the study.&#xD;
&#xD;
          8. Subjects with bleeding disorders or subjects who are taking thrombolytics or&#xD;
             anticoagulants, or have taken inhibitors of platelet aggregation, including&#xD;
             non-steroidal anti-inflammatory agents and acetylsalicylic acid, two weeks before&#xD;
             treatment.&#xD;
&#xD;
          9. Subjects on immunomodulatory therapy (suppressive or stimulatory).&#xD;
&#xD;
         10. Subjects with contraindications for MRI, such as presence of pacemaker, clips or&#xD;
             splinter, or tendency for claustrophobia.&#xD;
&#xD;
         11. Any condition which in the opinion of the Investigator makes the subject unsuitable&#xD;
             for inclusion (e.g., subjects not likely to participate for the duration of the&#xD;
             study).&#xD;
&#xD;
         12. Use of any investigational drugs or devices within 30 days prior to baseline.&#xD;
&#xD;
         13. Subjects who are study site staff for this study, or close relatives of the study site&#xD;
             staff, as well as subjects who are employed by the Sponsor company, or close relatives&#xD;
             of employees at the Sponsor company.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Hed√©n, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akademikliniken</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raphael Sinna, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Amiens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Raphael Sinna</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Per Heden</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>December 12, 2012</study_first_submitted>
  <study_first_submitted_qc>December 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pectus excavatum</keyword>
  <keyword>funnel chest</keyword>
  <keyword>sunken chest</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Funnel Chest</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

